Probiotic Bacillus subtilis Protects against α-Synuclein Aggregation in C. elegans

María Eugenia Goya, Feng Xue, Cristina Sampedro-Torres-Quevedo, Sofia Arnaouteli, Lourdes Riquelme-Dominguez, Andrés Romanowski, Jack Brydon, Kathryn L. Ball, Nicola R. Stanley-Wall, Maria Doitsidou

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Recent discoveries have implicated the gut microbiome in the progression and severity of Parkinson’s disease; however, how gut bacteria affect such neurodegenerative disorders remains unclear. Here, we report that the Bacillus subtilis probiotic strain PXN21 inhibits α-synuclein aggregation and clears preformed aggregates in an established Caenorhabditis elegans model of synucleinopathy. This protection is seen in young and aging animals and is partly mediated by DAF-16. Multiple B. subtilis strains trigger the protective effect via both spores and vegetative cells, partly due to a biofilm formation in the gut of the worms and the release of bacterial metabolites. We identify several host metabolic pathways differentially regulated in response to probiotic exposure, including sphingolipid metabolism. We further demonstrate functional roles of the sphingolipid metabolism genes lagr-1, asm-3, and sptl-3 in the anti-aggregation effect. Our findings provide a basis for exploring the disease-modifying potential of B. subtilis as a dietary supplement.
Original languageEnglish
Pages (from-to)367-380.e7
Number of pages21
JournalCell Reports
Issue number2
Publication statusPublished - 14 Jan 2020

Keywords / Materials (for Non-textual outputs)

  • probiotics
  • B. subtilis
  • C. elegans
  • α-synuclein
  • microbiota
  • Parkinson’s disease
  • DAF-16/FOXO
  • dietary restriction
  • sphingolipid metabolism
  • biofilm


Dive into the research topics of 'Probiotic Bacillus subtilis Protects against α-Synuclein Aggregation in C. elegans'. Together they form a unique fingerprint.

Cite this